1

SEQUENCE LISTING

```
<110> NAKAMURA, CHIKASHI
     MIYAKE, JUN
      OBATAYA, IKUO
     NAKAMURA, NORIYUKI
      SHIRAI, KATSUHISA
      INUYAMA, YASUHIRO
<120> DIOXIN-BINDING MATERIAL AND METHOD OF DETECTING OR QUANTIFYING
      DIOXIN
<130> 8156/88120
<140> 10/574,910
<141> 2006-04-07
<150> PCT/IB2004/003204
<151> 2004-10-04
<150> JP 2003-353026
<151> 2003-10-10
<160> 24
<170> PatentIn version 3.3
<210> 1
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<220>
<221> MOD_RES
<222> (1)
<223> Hydrophobic amino acid residue having a side
      chain with a cyclic group
<220>
<221> MOD RES
<222> (5)
<223> Hydrophobic amino acid residue having an aliphatic
      hydrocarbon group or an aromatic hydrocarbon group
<220>
<221> MOD_RES
<222> (6)
<223> Variable amino acid that may or may not be present
<400> 1
Xaa Leu Asp Gln Xaa Xaa
                5
```

```
<210> 2
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 2
Phe Leu Asp Gln Ile
<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 3
Phe Leu Asp Gln Val
<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<220>
<221> MOD_RES
<222> (1)
<223> 1-naphthylalanine
<400> 4
Xaa Leu Asp Gln Val
              <sub>.</sub> 5
<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
```

```
<220>
<221> MOD_RES
<222> (1)
<223> Cyclohexylalanine
<400> 5
Xaa Leu Asp Gln Val
                5
<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 6
Phe Ala Asp Gln Val
<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 7
Phe Phe Asp Gln Val
<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 8
Phe Ile Asp Gln Val
<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Synthetic
     peptide
<400> 9
Phe Met Asp Gln Val
         5
<210> 10
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<220>
<221> MOD_RES
<222> (2)
<223> Norleucine
<400> 10
Phe Xaa Asp Gln Val
<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 11
Phe Asn Asp Gln Val
<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 12
Phe Leu Ala Gln Val
      5
1
```

```
<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 13
Phe Leu Leu Gln Val
<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<220>
<221> MOD RES
<222> (3)
<223> Norvaline
<400> 14
Phe Leu Xaa Gln Val
1
                5
<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 15
Phe Leu Asn Gln Val
<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
```

```
<400> 16
Phe Leu Glu Gln Val
<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
<400> 17
Phe Leu Asp Ala Val
<210> 18
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 18
Phe Leu Asp Leu Val
      5
1
<210> 19
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<220>
<221> MOD_RES
<222> (4)
<223> Norleucine
<400> 19
Phe Leu Asp Xaa Val
<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 20
Phe Leu Asp Glu Val
<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 21
Phe Leu Asp Asn Val
<210> 22
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<220>
<221> MOD_RES
<222> (5)
<223> Phenylglycine
<400> 22
Phe Leu Asp Gln Xaa
<210> 23
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 23
Phe Leu Asp Gln Leu
                5
1
```

```
<210> 24
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic peptide
<220>
<221> MOD_RES
<221> MOD_RES
<222> (5)
<223> Norvaline
<400> 24
Phe Leu Asp Gln Xaa
```